Clinical experience with ertapenem in acute pyelonephritis due to ESBL producing enterobacteriaceae in India

Phase 4

• Conditions: Health Condition 1: null- Acute pyelonephritis due to ESBL producing enterobacteriaceae

• Registration Number: CTRI/2014/05/004637
• Lead Sponsor: MSD Pharmaceuticals

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 24 November 2021

Recruitment & Eligibility

• Status: Open to Recruitment
• Sex: Not specified
• Target Recruitment: 100

Inclusion Criteria

ï??Age: â?§18 years

ï??Diagnosis of Acute Pyelonephritis [i.e., patients with fever, flank pain or costvertebral angle tenderness, pyuria (>= 10 white blood cell per high power field)] and confirmed ESBL Enterobacteriaceae (as per CLSI, Vitek-2) on urine culture

ï??Patient received Ertapenem therapy (>=3 dose)

Exclusion Criteria

ï??Need for concomitant antimicrobials in addition to study therapy

ï??A history of coronary heart disease or stroke, serum Creatinine >1.5 mg/dl, albuminuria >40 μg/min, and use of lipid-lowering drugs, aspirin, or other antihypertensive agents.

Study & Design

• Study Type: PMS
• Study Design: Not specified